Non-alcoholic Fatty Liver Clinical Trials

91 recruitingLast updated: July 25, 2026

There are 91 actively recruiting non-alcoholic fatty liver clinical trials across 31 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include New York, New York, United States, San Antonio, Texas, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Non-alcoholic Fatty Liver Trials at a Glance

91 actively recruiting trials for non-alcoholic fatty liver are listed on ClinicalTrialsFinder across 6 cities in 31 countries. The largest study group is Not Applicable with 35 trials, with the heaviest enrollment activity in New York, San Antonio, and Boston. Lead sponsors running non-alcoholic fatty liver studies include GlaxoSmithKline, Cairo University, and The University of Hong Kong.

Browse non-alcoholic fatty liver trials by phase

Treatments under study

About Non-alcoholic Fatty Liver Clinical Trials

Looking for clinical trials for Non-alcoholic Fatty Liver? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non-alcoholic Fatty Liver trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non-alcoholic Fatty Liver clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 91 trials

Recruiting
Phase 2

Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

Non-Alcoholic Fatty Liver DiseaseNon Alcoholic Steatohepatitis
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)104 enrolled1 locationNCT03884075
Recruiting
Phase 2

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

Non-Alcoholic Fatty Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis
GlaxoSmithKline42 enrolled30 locationsNCT06920043
Recruiting
Not Applicable

Taiwan Green Propolis for Blood Lipids and Body Fat in Patients With MASLD

Obesity, OverweightMetabolic Dysfunction-Associated Steatotic Liver DiseaseNon-alcoholic Fatty Liver Disease NAFLD+1 more
Taipei Medical University60 enrolled1 locationNCT07692438
Recruiting
Phase 1

Effect of Insulin Lowering on Lipogenesis

ObesityInsulin ResistanceNon-Alcoholic Fatty Liver Disease+2 more
Columbia University25 enrolled1 locationNCT07403604
Recruiting
Not Applicable

Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients

Liver FibrosisNon-alcoholic Fatty Liver Disease NAFLDAlcoholic Liver Disease (ALD)
University Hospital, Angers1,788 enrolled13 locationsNCT05699018
Recruiting
Not Applicable

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

Insulin Sensitivity/ResistanceObesityInsulin Resistance+16 more
Pichamol Jirapinyo, MD, MPH132 enrolled2 locationsNCT06138821
Recruiting

Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme

ObesityLiver FibrosisMetabolic Dysfunction-Associated Steatotic Liver Disease+3 more
Hospital General Universitario Gregorio Marañon3,000 enrolled1 locationNCT07658755
Recruiting
Not Applicable

Exploratory Study of MRI Biomarkers of NASH

Non-alcoholic Fatty Liver Disease NAFLD
University Hospital, Angers110 enrolled2 locationsNCT06626074
Recruiting

Increased Risk of Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals

Non-Alcoholic Fatty Liver DiseaseLow Birth Weight
Steno Diabetes Center Copenhagen300 enrolled1 locationNCT05890365
Recruiting
Phase 1

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

Non-Alcoholic Fatty Liver Disease
GlaxoSmithKline32 enrolled3 locationsNCT07358546
Recruiting

Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease
Queen Mary University of London153 enrolled1 locationNCT04141592
Recruiting

A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes

NAFLD - Non-Alcoholic Fatty Liver DiseaseNAFLD and NASHNAFLD Cirrhosis
The Affiliated Hospital of Hangzhou Normal University20,000 enrolled1 locationNCT07241195
Recruiting

Identification of Liver Fibrosis Biomarkers

Non-Alcoholic Fatty Liver DiseaseNon Alcoholic SteatohepatitisNon-alcoholic Fatty Liver
Roche Diagnostics GmbH575 enrolled2 locationsNCT06819917
Recruiting
Phase 1

Evaluating the Pharmacokinetics and Safety of Miricorilant

Nonalcoholic Steatohepatitis (NASH)Non-alcoholic Fatty Liver Disease NAFLDMetabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis+1 more
Corcept Therapeutics15 enrolled1 locationNCT07553663
Recruiting
Not Applicable

Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues

Non-Alcoholic Fatty Liver DiseaseSubclinical hypothyroïdismPrimary Open Angle Glaucoma
Cairo University40 enrolled1 locationNCT07599241
Recruiting
Phase 2

Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients

Non-Alcoholic Fatty Liver Disease
Tanta University46 enrolled1 locationNCT06863376
Recruiting

Liver Steatosis in Pediatric CD Patients

Non-Alcoholic Fatty Liver DiseaseCeliac Disease in Children
University of Palermo91 enrolled2 locationsNCT06206616
Recruiting

CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome

Hepatocellular CarcinomaNon-Alcoholic Fatty Liver DiseaseNon Alcoholic Steatohepatitis+2 more
Institut National de la Santé Et de la Recherche Médicale, France710 enrolled1 locationNCT05623150
Recruiting
Phase 3

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Non-Alcoholic Fatty Liver Disease
GlaxoSmithKline1,200 enrolled49 locationsNCT07221227
Recruiting
Phase 3

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

Non-Alcoholic Fatty Liver Disease
GlaxoSmithKline1,250 enrolled43 locationsNCT07221188